What is Augmedics?
Augmedics is at the forefront of revolutionizing surgery by integrating augmented reality into the surgical image guidance process. The company's innovative solutions are designed to address critical unmet clinical needs, providing surgeons with enhanced visualization and precision. By augmenting surgery with advanced technologies, Augmedics aims to improve patient outcomes and streamline the surgical workflow, positioning itself as a key player in the MedTech industry. The company's commitment to technological advancement is evident in its pursuit of solutions that instill confidence and improve efficiency in complex surgical procedures.
How much funding has Augmedics raised?
Augmedics has raised a total of $141.8M across 4 funding rounds:
Series A
$8.3M
Series B
$15M
Unspecified
$36M
Series D
$82.5M
Series A (2017): $8.3M with participation from Terra Venture Partners and AO Invest
Series B (2020): $15M, investors not publicly disclosed
Unspecified (2021): $36M supported by Revival Healthcare Capital, Hospital Corporation of America, H.I.G. Capital, Almeda Ventures, and XR Investment
Series D (2023): $82.5M featuring Cpmg, Almeda Ventures, Revival Healthcare Capital, and H.I.G. Capital
Key Investors in Augmedics
Terra Venture Partners
Terra Venture Partners is an Israeli multi-stage venture capital firm focused on impact technology companies, often leading investments in digitalization and healthcare.
AO Invest
AO Invest, associated with Shenzhen Hongjiali New Energy Co., Ltd., specializes in electric vehicle charging solutions and integrated energy management, indicating a potential interest in broader technological infrastructure.
H.I.G. Capital
H.I.G. Capital is a global alternative investment firm with a focus on the mid-cap market, managing capital across various strategies including private equity and growth equity.
What's next for Augmedics?
With the recent infusion of $82.5M in a major strategic investment, Augmedics is poised for significant expansion and further technological development. This substantial capital injection, contributing to a total funding of $141.8M, signals strong investor confidence in the company's vision and market potential. The company is likely to leverage this financing to scale its operations, enhance its product offerings, and potentially explore new clinical applications for its AR-based surgical guidance system. Strategic partnerships and further research and development initiatives are anticipated as Augmedics continues to solidify its position as a leader in surgical innovation.
See full Augmedics company page
